

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/624,475	Ī	07/23/2003	Warren Hugh Finlay	364-1us	7427	
20212	7590	12/01/2005		EXAMINER		
THOMPSO			GEORGE, KONATA M			
SUITE 703D, CRYSTAL PARK TWO 2121 CRYSTAL DRIVE				ART UNIT	ART UNIT PAPER NUMBER	
ARLINGTO	N, VA	22202		1616		

DATE MAILED: 12/01/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	n No.	Applicant(s)						
	Office Assista Communication	10/624,475	;	FINLAY ET AL.						
	Office Action Summary	Examiner		Art Unit						
		Konata M.		1616						
Period fo	The MAILING DATE of this communication or or Reply	appears on the	cover sheet with the c	orrespondence ad	idress –					
THE - Externafter - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REI MAILING DATE OF THIS COMMUNICATIO insions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory per re to reply within the set or extended period for reply will, by stareply received by the Office later than three months after the material parent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no ever reply within the statut riod will apply and will atute, cause the applic	nt, however, may a reply be tim ory minimum of thirty (30) days expire SIX (6) MONTHS from to eation to become ABANDONED	ely filed s will be considered timel the mailing date of this c O (35 U.S.C. § 133).						
Status										
1)	Responsive to communication(s) filed on									
	2a) ☐ This action is FINAL . 2b) ☑ This action is non-final.									
3)	Since this application is in condition for allow	wance except fe	or formal matters, pro	secution as to the	e merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.									
Dispositi	on of Claims									
4)🖂	Claim(s) 1-13 is/are pending in the applicati	ion.		•						
	4a) Of the above claim(s) is/are withdrawn from consideration.									
5)	Claim(s) is/are allowed.				•					
6)⊠	Claim(s) <u>1-13</u> is/are rejected.									
7)	Claim(s) is/are objected to									
8)□	Claim(s) are subject to restriction and	d/or election red	quirement.							
Applicati	on Papers									
9) 🗌 🤈	The specification is objected to by the Exam	iner.								
10)🛛	10)⊠ The drawing(s) filed on <u>23 July 2003</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) 🔲	The oath or declaration is objected to by the	Examiner. Not	e the attached Office	Action or form P7	ГО-152.					
Priority u	ınder 35 U.S.C. § 119									
_	Acknowledgment is made of a claim for forei ☐ All b) ☐ Some * c) ☒ None of: 1. ☒ Certified copies of the priority docume			-(d) or (f).						
	2. Certified copies of the priority docume			on No						
	3. \square Copies of the certified copies of the p	riority documer	nts have been receive		Stage					
* 0	application from the International Bure	•		.i						
~ 5	see the attached detailed Office action for a l	ist of the certific	a copies not received	J.						
Attachment										
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date										
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 5) Notice of Informal Patent Application (PTO-152)										
Paper No(s)/Mail Date 6) Other:										

Art Unit: 1616

DETAILED ACTION

Claims 1-13 are pending in this application.

Drawings

1. The drawing(s) filed under 37 CFR 1.184 or 1.152 are accepted by the examiner.

Information Disclosure Statement

2. The information disclosure statement (IDS) submitted on June 21, 2004 was noted and the submission is in compliance with the provisions of 37 CFR 1.97.

Accordingly, the examiner has considered the information disclosure statement.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- 3. Claims 1 and 5 are rejected under 35 U.S.C. 102(a) as being anticipated by Maitra et al. (US 6,579,519 B2).

Maitra et al. discloses a preparation of nanoparticles comprising a drug, wherein the polymeric micelles nanoparticles are mixed with an alcoholic solution followed by lyophilizing the micelle to get a dry powder for subsequent use (col. 8, lines 38-49).

Application/Control Number: 10/624,475

Art Unit: 1616

4. Claims 1, 3-5 and 7-13 are rejected under 35 U.S.C. 102(a) as being anticipated by Edwards et al. (WO 03/043586 A2).

Edwards et al. discloses a process for formulating particles comprising a "feed solution" of "feed mixture" comprising nanoparticles and one or more additives that are fed to a spray dryer (page, 9, lines 9-12). Lines 13-24 teach that organic and aqueous solvents can be present in the mixture. Bioactive agents having therapeutic, diagnostic and prophylactic properties, nutraceutical agents, radioactive material i.e. by¹²⁵I, ¹³¹I, ³⁵S and ³H, etc. (page 12, line 19 through page 16, lines 8). Page 22, lines 12-13 teach that the particles of the composition are suitable for pulmonary use. Page 23, lines 27-30 teach that the particles size is at least 5 microns.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 2 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Edwards et al. (WO 03/043586 A2) as applied to claims 1 and 3-5 and 7-13 above.

Edwards et al. discloses a process for formulating particles comprising a "feed solution" of "feed mixture" comprising nanoparticles and one or more additives that are fed to a spray dryer (page, 9, lines 9-12). Lines 13-24 teach that organic and aqueous solvents can be present in the mixture. Bioactive agents having therapeutic, diagnostic

and prophylactic properties, nutraceutical agents, radioactive material i.e. by ¹²⁵l, ¹³¹l, ³⁵S and ³H, etc. (page 12, line 19 through page 16, lines 8). Page 22, lines 12-13 teach that the particles of the composition are suitable for pulmonary use. Page 23, lines 27-30 teach that the particles size is at least 5 microns. A prima facie case of obviousness exists where the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected them to have the same properties. *Titanium Metals Corp. of America v. Banner*, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985). The prior art does not teach breaking up the dried mixture.

While the prior art does not explicitly teach breaking up a dried mixture, in column 6, lines 52-56 teach a solvent evaporation of the particles while stirring. It is the position of the examiner that stirring the particle mixture while drying would prevent the particles from clumping. Therefore, it is the position of the examiner that it would have been obvious to one of ordinary skill in the art at the time the invention was made to break up the dried mixture of particles in any manner to facilitate the aerosol delivery of the particles to the lung.

Conclusion

6. Claims 1-13 are rejected.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is

Application/Control Number: 10/624,475

Art Unit: 1616

(571) 272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday

to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for

the organization where this application or proceeding is assigned are (571) 273-8000 for

regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is

(571) 272-1600.

Konata M. George

SREENI PADMANABHAN

Page 5